How America's first CRISPR medicine treats sickle cell disease, explained for a 12-year-old and for an adult
In December 2023, the US FDA approved Casgevy, the first FDA-approved medicine to use CRISPR/Cas9 genome editing, treating sickle cell disease by increasing the production of fetal hemoglobin that prevents red blood cells from sickling. Checked 11 October 2026.
93.5%of evaluable trial patients (29 of 31) free from severe crises for at least 12 consecutive months44patients treated with Casgevy in the FDA approval trial100%achieved successful engraftment with zero graft rejections
Sickle cell disease is caused by an inherited mutation in hemoglobin, causing red blood cells to develop a crescent or sickle shape that restricts blood flow and starves tissues of oxygen, leading to severe pain called vaso-occlusive crises. But the body also carries a recipe for fetal hemoglobin (HbF), which facilitates oxygen delivery without sickling. As the US Food and Drug Administration recorded in its approval announcement, Casgevy uses CRISPR to modify blood stem cells to turn that fetal production back up.
Doctors harvest root cells from your bone marrow that grow into all your blood. In a laboratory dish, they send in microscopic chemical scissors to edit the instruction code.
The edited seeds are pumped back into your veins. They settle into the marrow soil, take root, and start churning out round, smooth baby blood cells that carry oxygen easily.
Because baby blood cannot form jagged clumps, your red blood cells stay soft and cushiony like water balloons, slipping smoothly through tiny vessels without causing traffic jams.
The FDA notes that patients who receive the treatment “will be followed in a long-term study to evaluate each product’s safety and effectiveness.” Rather than fixing the mutated adult hemoglobin gene directly, the therapy demonstrates that genetically modified blood stem cells can prompt the body to manufacture red blood cells that increase fetal hemoglobin and prevent sickling.